



Search results

🔍 remdesivir

19 August 2022

WHO makes new recommendations for Ebola treatments, calls for improved access

recommendation on therapeutics that should not be used to treat patients: these include ZMapp and **remdesivir**

8 August 2022

Safety and monitoring in patients receiving remdesivir for COVID-19

Safety and monitoring in patients receiving **remdesivir** for COVID-19

8 August 2022

Administration of Remdesivir for COVID-19

Administration of **Remdesivir** for COVID-19

8 August 2022

Remdesivir for COVID-19

21 April 2022

WHO recommends highly successful COVID-19 therapy and calls for wide geographical distribution and transparency from originator

recommendation for the use of nirmatrelvir and ritonavir, WHO has also updated its recommendation on **remdesivir**, WHO now suggests the use of **remdesivir** in mild or moderate COVID-19 patients who are at high risk of, The recommendation for use of **remdesivir** in patients with severe or critical COVID-19 is currently under

9 March 2022

Medical Product Alert N°2/2022: Falsified DESREM (Remdesivir)

Medical Product Alert N°2/2022: Falsified DESREM (**Remdesivir**), Alert Summary This WHO Medical Product Alert refers to two falsified batches of DESREM **Remdesivir** for, manufacturer, established that they do not contain any of the stated active pharmaceutical ingredient (**remdesivir** , Table 1: Products subject of WHO

13 August 2021

Medical Product Alert N°4/2021: Falsified remdesivir

Medical Product Alert N°4/2021: Falsified **remdesivir**, Alert Summary This WHO Medical Product Alert refers to two batches of falsified **remdesivir** injection, However, GILEAD has confirmed that the **remdesivir** products listed in this alert are falsified and were, **Remdesivir** is a broad-spectrum antiviral medication that was approved

11 August 2021


WHO's Solidarity clinical trial enters a new phase with three new candidate drugs

The results showed that **remdesivir**, hydroxychloroquine, lopinavir and interferon had little or no effect

31 March 2021

WHO advises that ivermectin only be used to treat COVID-19 within clinical trials


their use in patients with mild/moderate COVID-19 Conditional recommendation against administering **remdesivir**



20 November 2020

WHO recommends against the use of remdesivir in COVID-19 patients

WHO recommends against the use of **remdesivir** in COVID-19 patients, WHO has updated its recommendation on **remdesivir** for the treatment of COVID-19., from a clinical trial looking at the outcome of admission to hospital, WHO now suggests the use of **remdesivir** , in hospitalized patients, regardless of disease severity, as



16 October 2020

WHO Director-General's opening remarks at the media briefing on COVID-19 - 16 October 2020

results from the Solidarity Therapeutics Trial now show that the other two drugs in the trial, **remdesivir** , Interim results from the trial now show that the other two drugs in the trial, **remdesivir** and interferon

15 October 2020

Solidarity Therapeutics Trial produces conclusive evidence on the effectiveness of repurposed drugs for COVID-19 in record time

from the Solidarity Therapeutics Trial, coordinated by the World Health Organization, indicate that **remdesivir**

7 July 2020

Iran: WHO provides multiple shipments of critical COVID-19 supplies

Earlier on 16 June 2020, WHO delivered 2200 vials of **remdesivir** (a broad-spectrum antiviral medication

2 July 2020

Global scientific community unites to track progress on COVID-19 R&D, identifies new research priorities and critical gaps

other completed and ongoing trials for potential therapeutics: hydroxychloroquine, lopinavir/ritonavir, **remdesivir**

29 June 2020

Listings of WHO's response to COVID-19

Interim results from the Solidarity Trial indicated that **remdesivir** , hydroxychloroquine, lopinavir/ritonavir, COVID-19, with new information for clinicians including a conditional recommendation against the use of **remdesivir**

20 February 2020

WHO Director-General's opening remarks at the media briefing on COVID-19 on 20 February 2020

One combines two drugs for HIV, lopinavir and ritonavir, and the other is testing an antiviral called **remdesivir**

2 June 2018

Marburg virus disease

Remdesivir and Favipiravir that have been used in clinical studies for Ebola Virus Disease (EVD) that

Regions

- [Africa](#)
- [Americas](#)
- [Eastern Mediterranean](#)
- [Europe](#)
- [South-East Asia](#)
- [Western Pacific](#)

Policies

- [Cyber security](#)
- [Ethics](#)
- [Permissions and licensing](#)
- [Preventing sexual exploitation](#)
- [Terms of use](#)

About us

- [Careers](#)
- [Library](#)
- [Procurement](#)
- [Publications](#)
- [Frequently asked questions](#)
- [Contact us](#)

[Subscribe to our newsletters](#)



**World Health
Organization**